Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.
Its lead product candidate is CTI-1601, which is in Phase 2 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease.
The company is headquartered in Bala Cynwyd, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 24 | -0.27 Decreased by -80.00% | -0.23 Decreased by -17.39% |
| Feb 12, 24 | -0.30 Decreased by -42.86% | -0.25 Decreased by -20.00% |
| Nov 14, 23 | -0.21 Increased by +43.24% | -0.22 Increased by +4.55% |
| Aug 10, 23 | -0.19 Increased by +59.57% | -0.19 |
| May 15, 23 | -0.15 Increased by +69.39% | -0.25 Increased by +40.00% |
| Mar 14, 23 | -0.21 Increased by +58.00% | -0.37 Increased by +43.24% |
| Nov 10, 22 | -0.37 Increased by +59.78% | -0.42 Increased by +11.90% |
| Aug 11, 22 | -0.47 Increased by +40.51% | -0.57 Increased by +17.54% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0.00 Decreased by N/A% | -9.06 M Decreased by -11.53% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -8.37 M Increased by +3.25% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -5.42 M Increased by +39.83% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -8.41 M Increased by +7.92% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -8.13 M Increased by +51.64% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -8.65 M Increased by +31.42% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -9.00 M Increased by +25.55% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -9.13 M Increased by +35.69% | Decreased by N/A% Decreased by N/A% |